Delayed Defense: Type 4 Hypersensitivity Quiz

Type IV hypersensitivity is unique among the hypersensitivity types because it is entirely cell-mediated rather than antibody-mediated. It is driven primarily by antigen-specific T cells, particularly CD4 Th1 cells and CD8 cytotoxic T cells. The reaction develops slowly, peaking 48 to 72 hours after antigen re-exposure, which is why it is called delayed-type hypersensitivity (DTH).

Contact dermatitis is a well-recognized example of Type IV hypersensitivity. Haptens such as urushiol from poison ivy or nickel ions bind to skin proteins, forming neoantigens that are processed by Langerhans cells and presented to T cells. On re-exposure, sensitized CD4 and CD8 T cells are activated and migrate to the skin, releasing cytokines that recruit macrophages and cause the characteristic itching, redness, and blistering.

CD4 Th1 cells are the primary orchestrators of classic delayed-type hypersensitivity reactions. Upon encountering antigen presented on MHC class II molecules, Th1 cells produce IFN-gamma and TNF, which activate macrophages and recruit additional immune cells to the site. This macrophage-dominated inflammatory response is responsible for the tissue damage and induration characteristic of Type IV hypersensitivity reactions.

The tuberculin skin test (Mantoux test) is a diagnostic application of Type IV hypersensitivity. Purified protein derivative from Mycobacterium tuberculosis is injected intradermally. In a sensitized individual, memory Th1 cells recognize tuberculin antigens and release IFN-gamma, activating macrophages and causing induration and erythema that peaks at 48 to 72 hours. A positive reaction indicates prior exposure or sensitization to tuberculosis.

Type IV hypersensitivity is driven by T cell-derived cytokines. IFN-gamma produced by Th1 cells is central to macrophage activation and granuloma formation. TNF-alpha promotes endothelial activation and amplifies local inflammation. IL-17, produced by Th17 cells, drives neutrophil recruitment and is important in certain contact hypersensitivity and autoimmune variants of Type IV reactions. IL-4 and IL-5 are Th2 cytokines associated with Type I responses, not Type IV.

Granuloma formation is a hallmark of chronic Type IV hypersensitivity. When macrophages are unable to destroy a persistent antigen, such as in tuberculosis or sarcoidosis, they are continuously activated by Th1-derived IFN-gamma. Macrophages fuse to form multinucleated giant cells and are surrounded by a rim of lymphocytes, forming a granuloma. This structure walls off the antigen but can cause significant tissue damage and dysfunction over time.

In Type IV hypersensitivity, antigen-presenting cells such as dendritic cells, macrophages, and Langerhans cells in the skin process antigens and present peptide fragments on MHC class II molecules to CD4 T cells, or on MHC class I molecules to CD8 T cells. This MHC-dependent antigen presentation is essential for activating the T cells that drive the delayed inflammatory response.

CD8 cytotoxic T cells contribute to Type IV hypersensitivity, particularly in contact hypersensitivity and viral-triggered reactions. Upon activation, they recognize antigen presented on MHC class I molecules on target cells and release perforin, which forms pores in the target cell membrane, and granzymes, which activate intracellular apoptotic pathways. This direct cytotoxic mechanism contributes to the tissue damage and blistering seen in severe contact dermatitis.

Type IV hypersensitivity underlies several important clinical conditions. Granuloma formation in tuberculosis results from persistent Th1-driven macrophage activation around mycobacteria. Contact dermatitis involves Th1 and CD8 T cell responses to skin haptens. Rheumatoid arthritis involves Th1 and Th17 cytokines driving synovial inflammation and joint destruction. Autoimmune hemolytic anemia is a Type II antibody-mediated condition, not Type IV.

Corticosteroids are the mainstay treatment for severe Type IV hypersensitivity reactions such as extensive contact dermatitis. They suppress immune responses by inhibiting NF-kB-driven pro-inflammatory cytokine production, reducing T cell activation, suppressing macrophage activity, and decreasing the expression of adhesion molecules needed for immune cell recruitment. Topical corticosteroids manage mild skin reactions, while systemic corticosteroids are used for more severe or widespread responses.

Type IV hypersensitivity proceeds in two phases. During sensitization, antigen-presenting cells process the antigen and prime naive T cells, generating a pool of antigen-specific memory T cells. No symptoms occur at this stage. During elicitation, re-exposure to the antigen rapidly activates memory T cells, leading to cytokine release, macrophage activation, and the characteristic delayed inflammatory tissue damage seen 48 to 72 hours later.

Allergic contact dermatitis is a chronic form of Type IV hypersensitivity in which repeated skin exposure to sensitizing haptens such as nickel, fragrances, or latex drives persistent T cell-mediated inflammation. Each exposure reactivates sensitized T cells, causing recurrent episodes of pruritic, erythematous, vesicular skin lesions. Patch testing is used clinically to identify the specific contact allergen responsible for triggering the response.

Type IV hypersensitivity is fundamentally different from antibody-mediated types. It is driven by T cells, not antibodies, so it cannot be transferred between individuals using serum alone but can be transferred with sensitized T cells. The delayed kinetics, peaking at 48 to 72 hours, reflect the time needed for T cell recruitment and macrophage activation. IgG and complement are hallmarks of Type II and III, not Type IV reactions.

IFN-gamma produced by Th1 cells is a potent macrophage activator. Activated macrophages upregulate their microbicidal mechanisms including reactive oxygen species, nitric oxide production, and lysosomal enzyme activity, enhancing their ability to destroy intracellular pathogens. However, when this activation is excessive or prolonged, as in chronic Type IV hypersensitivity, the same destructive mechanisms damage surrounding healthy tissues, contributing to the pathology of conditions like tuberculosis and Crohn's disease.

Type IV hypersensitivity is called delayed because the cellular immune mechanisms underlying it take considerably longer to develop than antibody-mediated reactions. Memory T cells must be recruited to the site, recognize antigen on MHC molecules, become activated, and release cytokines that then recruit and activate macrophages. This entire cascade requires 48 to 72 hours to produce visible inflammatory signs, in contrast to the immediate minutes-long response of Type I hypersensitivity.